ClinicalTrials.gg

Program

7MW3711 for injection

Also written as “7MW3711”.

Its studies are led by Mabwell (Shanghai) Bioscience.

Furthest: phase 3, since Sep 4, 20263 company-led studies, 3 open or runningNext primary completion: Mar 2029 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Mabwell (Shanghai) Bioscience33 open or runningphase 3since Sep 4, 2026Aug 7, 2023Mar 2029phase 3 · NCT07831863

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 7, 2023First studies: 2 phase 2 studies in Advanced Solid TumorFirst studyNCT06008379, NCT06008366
  2. Sep 4, 2026Phase 3 study in Lung Squamous Cell CarcinomaPhase 3 reachedNCT07831863 · 600 planned · China

Ahead

  1. Mar 2029Primary completion: phase 3 study in Lung Squamous Cell CarcinomaNCT07831863

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07831863Lung Squamous Cell Carcinoma · China3Not yet recruitingMar 2029600
NCT06008379Advanced Solid Tumor · China2RecruitingAug 30, 2025164
NCT06008366Advanced Solid Tumor · China2RecruitingAug 30, 2025281

How it is read

Names in the registry

  • “7MW3711 for injection”, 4 entries
  • “7MW3711”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.